{"id":"W2127154017","doi":"10.1016/j.ctrv.2009.08.001","title":"Irreversible pan-ErbB tyrosine kinase inhibitors and breast cancer: Current status and future directions","year":2009,"lang":"en","type":"review","venue":"Cancer Treatment Reviews","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Genentech; Pfizer","keywords":"Lapatinib; Medicine; Trastuzumab; Tyrosine kinase; Receptor tyrosine kinase; Breast cancer; Tyrosine-kinase inhibitor; ErbB; Monoclonal antibody; Cancer research; Cancer; Pharmacology; Internal medicine; Receptor; Immunology; Antibody","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006652441,0.0009534736,0.002144184,0.00134338,0.0002128577,0.0009416626,0.0009034623,0.0009191245,0.005638304],"category_scores_gemma":[0.0005895989,0.000288382,0.000544876,0.001808344,0.0004057281,0.001396736,0.0004707174,0.001581304,0.002170868],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005366543,"about_ca_system_score_gemma":0.0009316072,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009111029,"about_ca_topic_score_gemma":0.003371754,"domain_scores_codex":[0.9998338,0.00002630456,0.0000232183,0.00003044659,0.00006452783,0.00002167181],"domain_scores_gemma":[0.999731,0.0001385296,0.00005248954,0.000007327832,0.00004960305,0.00002107233],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001741868,0.0001145501,0.0001330626,0.01011898,0.00008986692,0.0001458299,0.00002645068,0.0004312173,0.001699335,0.001755128,0.02638552,0.9589259],"study_design_scores_gemma":[0.0001158923,0.0003295623,0.001030025,0.002961406,0.0003743208,0.001392121,0.0000607536,0.0002604853,0.0008972411,0.001647704,0.9909044,0.00002606394],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0001505793,0.9987791,0.0001179967,0.0001659713,0.0001097831,0.000004205726,0.00001476678,0.000008091524,0.0006495715],"genre_scores_gemma":[0.0007042547,0.9983205,0.0001826541,0.0001481123,0.00009195615,0.000004862796,0.00002366696,0.000001198657,0.0005226942],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.005638304,"threshold_uncertainty_score":0.01886201,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08835437902740187,"score_gpt":0.4363174976594466,"score_spread":0.3479631186320448,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}